계명대학교 의학도서관 Repository

Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement

Metadata Downloads
Author(s)
Byung Woog KangJoon Ho MoonYee Soo ChaeSoo Jung LeeJong Gwang KimYeo-Kyeoung KimJe-Jung LeeDeok-Hwan YangHyeoung-Joon KimJin Young KimYoung Rok DoKeon Uk ParkHong Suk SongKi Young KwonMin Kyung KimKyung Hee LeeMyung Soo HyunHun Mo RyooSung Hwa BaeHwak KimSang Kyun Sohn
Keimyung Author(s)
Kim, Jin YoungDo, Young RokPark, Keon UkSong, Hong SukKwon, Ki Young
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Research and Treatment
Issued Date
2013
Volume
45
Issue
2
Abstract
Purpose : We investigated the clinical outcome of bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.
Materials and Methods : A total of 567 consecutive patients with newly diagnosed DLBCL treated with rituximab-CHOP (RCHOP) between November 2001 and March 2010 were included in the current study. All of the patients underwent a BM study at the initial staging and the clinical characteristics and prognosis of these patients with or without BM involvement were analyzed retrospectively.
Results : The total cohort included 567 patients. The overall incidence of BM involvement was 8.5%. With a median follow-up duration of 33.2 months (range, 0.1 to 80.7 months) for patients who were alive at the last follow-up, the five-year overall survival (OS) and event-free survival (EFS) rate in patients without BM involvement (76.3% and 67.5%, p<0.001) was statistically higher than that in patients with BM involvement (44.3% and 40.1%, p<0.001). In multivariate analysis, among total patients, BM involvement showed a significant association with OS and EFS. In univariate and multivariate analyses, even among stage IV patients, a significant association with worse EFS was observed in the BM involvement group.
Conclusion : BM involvement at diagnosis affected the survival of patients with DLBCL who received RCHOP. Although use of RCHOP can result in significant improvement of the therapeutic effect of DLBCL, BM involvement is still a negative prognostic factor of DLBCL patients in the era of rituximab.
Key words: Diffuse large B-cell lymphoma, Bone marrow, Rituximab
Keimyung Author(s)(Kor)
김진영
도영록
박건욱
송홍석
권기영
Publisher
School of Medicine
Citation
Byung Woog Kang et al. (2013). Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement. Cancer Research and Treatment, 45(2), 112–117. doi: 10.4143/crt.2013.45.2.112
Type
Article
ISSN
1598-2998
DOI
10.4143/crt.2013.45.2.112
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35344
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.